Development of a Multivalent Rhinovirus Vaccine

Rhinovirus (RV), known as the primary cause of the common cold, also has a critical role causing asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis in infant, geriatric, or immunocompromised patients. Despite the demand for an efficient RV vaccine, there are several obstacles, notably, the large number of serotypes of RVs. To overcome this challenge, we have identified centroids of clusters by bioinformatics analysis and is developing a multivalent recombinant protein vaccine.

This study will provide feedback to bioinformatics analysis tools and advance protein technology with the ultimate goal of developing a multi-valent RV vaccine.